Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0468 • ACR Convergence 2024
Plasma Calprotectin Assessed in Multiple Biological Treatment Strategies for Early Rheumatoid Arthritis over 48 Weeks
David Stevens¹, Lene Sundbakk², Amirhossein Kazemi², Marte Heiberg³, Tuulikki Sokka-Isler⁴, Bjorn Gudbjornsson⁵, Kristina Lend⁶, Anna Rudin⁷, Michael Nurmohamed⁸, Jon Lampa⁹, Merete Hetland¹⁰, Mikkel Ostergaard¹¹, Ronald Van Vollenhoven¹², Tillmann Uhlig², Espen Haavardsholm² and Hilde Hammer³, ¹St. Olavs hospital, Trondheim, Norway, ²Diakonhjemmet Hospital, Oslo, Norway, ³Diakonhjemmet Hospital, Oslo, Oslo, Norway, ⁴University of Eastern Finland, Faculty of Health Sciences, Jyvaskyla, Finland, ⁵Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ⁶Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ⁷Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, ⁸Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁹Karolinska University Hospital, Hässelby, Sweden, ¹⁰Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ¹¹Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ¹²Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Plasma calprotectin is a sensitive biomarker of inflammation in patients with rheumatoid arthritis (RA) and reflects activation of granulocytes and macrophages. Calprotectin has not…
Abstract Number: 0485 • ACR Convergence 2024
Biomarkers for Disease Activity and Response to Treatment in Early Rheumatoid Arthritis: Metabolomics and Machine Learning Analyses in NORD-STAR Cohort
Tahzeeb Fatima¹, Yuan Zhang², Georgios Vasileiadis², Araz Rawshani², Ronald Van Vollenhoven³, Jon Lampa⁴, Bjorn Gudbjornsson⁵, Espen Haavardsholm⁶, Dan Nordstrom⁷, Gerdur Gröndal⁵, Kim Hørslev-Petersen⁸, Kristina Lend⁹, Marte Heiberg¹⁰, Merete Hetland¹¹, Michael Nurmohamed¹², Mikkel Ostergaard¹³, Tillmann Uhlig⁶, Tuulikki Sokka-Isler¹⁴, Anna Rudin¹⁵ and Cristina Maglio², ¹University of Gothenburg, Göteborg, Sweden, ²University of Gothenburg, Gothenburg, Sweden, ³Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁴Karolinska University Hospital, Hässelby, Sweden, ⁵Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Helsinki University Hospital, Helsinki, Finland, ⁸University Hospital of Southern Denmark, Sønderborg, Denmark, ⁹Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ¹⁰Diakonhjemmet Hospital, Oslo, Oslo, Norway, ¹¹Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ¹²Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹³Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ¹⁴Jyväskylä Central Hospital, Jyväskylä, Finland, ¹⁵Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: The variability in treatment response in people with rheumatoid arthritis (RA) warrants the prediction of patients at high risk of treatment failure. Identification of…
Abstract Number: 0502 • ACR Convergence 2024
Similar Efficacy, PK, Safety, and Immunogenicity of Tocilizumab Biosimilar (CT-P47) and Reference Tocilizumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Week 52 Results from the Phase III Single Transition Study
Gerd Burmester¹, Jakub Trefler², Artur Racewicz³, Janusz Jaworski⁴, Agnieszka Zielińska⁵, Marek Krogulec⁶, Sławomir Jeka⁷, Rafał Wojciechowski⁸, Katarzyna Kolossa⁹, Anna Dudek¹⁰, Magdalena Krajewska-Włodarczyk¹¹, Paweł Hrycaj¹², Piotr Adrian Klimiuk¹³, SungHyun Kim¹⁴, JeeHye Suh¹⁴, GoEun Yang¹⁴, Yunah Kim¹⁴, YooBin Jung¹⁴, JiWoo Hong¹⁴ and Josef Smolen¹⁵, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²REUMA RESEARCH, Wrocław, Poland, ³Zdrowie Osteo-Medic, Warszawa, Poland, ⁴Reumatika-Centrum Reumatologii, Warszawa, Poland, ⁵MICS Centrum Medyczne Warszawa, Warszawa, Poland, ⁶NZOZ Lecznica MAK - MED, Nadarzyn, Poland, ⁷MICS Centrum Medyczne, Polska, Poland, ⁸Department of Rheumatology and Systemic Connective Tissue Diseases, University Hospital No. 2, Bydgoszcz, PL, Bydgoszcz, Poland, ⁹MICS Centrum Medyczne Bydgoszcz, Bydgoszcz, Poland, ¹⁰Centrum Medyczne Amed, Warszawa, Poland, ¹¹University of Warmia and Mazury, Clinic of Rheumatology, Olsztyn, Poland, ¹²Prywatna Praktyka Lekarska Prof. dr hab. med. Paweł, Poznań, Poland, ¹³Medical University of Bialystok and Inter Clinic Piotr Adrian Klimiuk, Department of Rheumatology and Internal Diseases, Białystok, Poland, ¹⁴Celltrion, Inc., Incheon, Republic of Korea, ¹⁵Medical University of Vienna, Vienna, Austria
Background/Purpose: The therapeutic equivalence of CT-P47 (a proposed biosimilar to reference tocilizumab [ref-tocilizumab]) was demonstrated in patients with moderate to severe RA through disease activity…
Abstract Number: 0519 • ACR Convergence 2024
Comparable Malignancy Risk of Janus Kinase Inhibitors with Conventional Synthetic and Biologic DMARDs in Asian Patients with Rheumatoid Arthritis: A Comprehensive Analysis from Two Medical Centers
Ming‑Han Chen¹, Mao-Yuan Chen², Shih-Hsin Chang³ and DER-YUAN CHEN⁴, ¹Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan, ²Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan (Republic of China), ³Rheumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan (Republic of China), ⁴heumatology and Immunology Center, China Medical University Hospital, Taichung, Taiwan (Republic of China)
Background/Purpose: JAK inhibitors (JAKi) and biologic disease-modifying antirheumatic drugs (bDMARDs) have proven efficacy in the treatment of rheumatoid arthritis (RA). However, their potential for increasing…
Abstract Number: 0536 • ACR Convergence 2024
A Population Modeling and Simulation of the Effect of Obexelimab Exposure on the QTc Interval in Healthy Volunteers and Patients with Rheumatoid Arthritis or IgG4-Related Disease
Claire Mukashyaka¹, Xiaodong Wang¹, Sujata Arora¹, Mason Yamashita¹, Allen Poma¹ and Tanya Fischer², ¹Zenas BioPharma, Waltham, MA, ²Zenas BioPharma, Waltham, CA
Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B cells, CD19-expressing plasma cells, and plasmablast activity and has the potential to provide clinical benefit…
Abstract Number: 0867 • ACR Convergence 2024
Development of a Remote Patient Monitoring System Based on a Novel Digital Biomarker for Swelling in Rheumatoid Arthritis
Marc Blanchard¹, Cinja Koller², Jules Maglione³, Patrick Hermann¹ and Thomas Hügle³, ¹Lausanne University Hospital, Lausanne, Vaud, Switzerland, ²Doctoral School, Faculty of Biology and Medicine, University of Lausanne, Genève, Vaud, Switzerland, ³Lausanne University Hospital, Lausanne, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) care faces challenges due to a shortage of healthcare providers, an increasing patient population and the remote locations of many patients.…
Abstract Number: 0928 • ACR Convergence 2024
In Vitro Study of Fibroblast-Like Synoviocytes and Macrophages-Like Synoviocytes Isolated from Rheumatoid Arthritis, Psoriatic Arthritis Patients and Healthy Subjects
monia Maccaferri¹, Francesco Zambianchi², Carlo Salvarani³ and Elisa Pignatti³, ¹Azienda Ospedaliero Universitaria di Modena, Modena, Italy, ²Department of Maternal, Child and Adult Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy, ³Department of Surgery, Medicine Dentistry and Morphological Sciences with Interest in Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
Background/Purpose: Interactions between fibroblast-like synoviocytes (FLSs) and macrophage-like synoviocytes (MLSs) are pivotal in the pathogenesis of RA and PsA. FLSs both activate and are activated…
Abstract Number: 0977 • ACR Convergence 2024
Vaccine Effectiveness and Safety of Recombinant Zoster Vaccine (RZV) in Rheumatoid Arthritis (RA) Patient Populations Aged 50 Years and Older
Emily Rayens¹, Lina Sy¹, Lei Qian¹, Jun Wu¹, Bradley Ackerson¹, Yi Luo¹, Yanjun Cheng¹, Antony Lin¹, Zendi Solano¹, Justine De Jesus¹, Britta Amundsen¹, Ana Florea¹, Jen Ku¹, Elizabeth Chmielewski-Yee², Driss Oraichi², Harry Seifert², Huifeng Yun² and Hung-Fu Tseng¹, ¹Kaiser Permanente Southern California, Pasadena, CA, ²GSK, Rockville, MD
Background/Purpose: Individuals with rheumatoid arthritis (RA) are at higher risk of herpes zoster (HZ) compared to the general population. This interim analysis evaluated the vaccine…
Abstract Number: 1032 • ACR Convergence 2024
Impact of a Coordinated Care Model for Addressing Rheumatoid Arthritis and Associated Comorbidities
Alexis Barbut¹, Marsha Jackson², Krista Kowiak², Julie McIntyre² and Allen Anandarajah¹, ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester Medical Center, Rochester
Background/Purpose: Rheumatoid Arthritis (RA) is often associated with comorbidities including hypertension, cardiovascular disease, osteoporosis, lung disease, and eye involvement. Studies suggests that the average RA…
Abstract Number: 1217 • ACR Convergence 2024
Medical and Non-Medical Cannabis Use by Rheumatology Patients: A Study of over 2000 Patients in California
Maggie Hui¹, Nicholas Jackson², Angela Pham¹, Keren Chen², David Elashoff², ziva Cooper³ and Veena Ranganath⁴, ¹David Geffen School of Medicine at UCLA, Los Angeles, ²UCLA Department of Medicine Statistics Core, Los Angeles, ³UCLA Center for Cannabis and Cannabinoids, Semel Institute for Neuroscience & Human Behavior, Dept of Psychiatry and Biobehavioral Sciences, Dept of Anesthesiology and Perioperative Medicine, Los Angeles, ⁴UCLA, Los Angeles, CA
Background/Purpose: Approximately 12-20% of Rheumatology patients use cannabis (Fitzcharles 2020, Wipfler 2022, Rampakakis 2023). Despite the legalization of medical cannabis in California more than 2…
Abstract Number: 1334 • ACR Convergence 2024
Assessing the Performance of Validated Frailty Instruments in Veterans with Rheumatoid Arthritis (RA)
Kylie Riggles¹, Hannah Brubeck², Riley Bass³, Courtney Loecker⁴, Punyasha Roul⁵, Bryant England⁶, Elizabeth Wahl⁷, James Andrews⁸, Namrata Singh⁹, Joshua Baker¹⁰, Patti Katz¹¹, Dolores Shoback¹², Jose Garcia¹³, ariela orkaby¹⁴ and Katherine Wysham¹⁵, ¹VA Puget Sound Health Care System, Bellevue, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³VA Puget Sound Health Care System, Gig Harbor, WA, ⁴University of Nebraska, Lincoln, NE, ⁵UNMC, Omaha, NE, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷VA Puget Sound Healthcare System, Seattle, WA, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹University of Washington, Bellevue, WA, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹UCSF, San Rafael, CA, ¹²San Francisco VA/University of California, San Francisco, San Francisco, CA, ¹³VA Puget Sound Health Care System/University of Washington, Seattle, WA, ¹⁴New England VA Geriatric Research Education and Clinical Center/Boston VA/Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹⁵VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA
Background/Purpose: Frailty is a state of decreased physiological reserve that confers an increased vulnerability to stressors and adverse outcomes1. Compared to the general population, frailty…
Abstract Number: 1350 • ACR Convergence 2024
Relationship Between Salivary and Stool Microbiome with Disease Activity and Vascular Function in Patients with Rheumatoid Arthritis
Tulsi Joishy, Sheau-Chiann Chen, Qiong Wu and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease affecting the joints that is associated with increased cardiovascular risk. Environmental factors play a crucial role…
Abstract Number: 1366 • ACR Convergence 2024
Methotrexate Maintenance in Rheumatoid Arthritis, Two Years After Initiation of a First Targeted Therapy: Results from the Prospective STRATEGE2 Study
Cécile Gaujoux-Viala¹, Emmanuelle Dernis², Eric Senbel³, Hélène Herman-Demars⁴ and René-Marc Flipo⁵, ¹CHU Nîmes, Nïmes, Languedoc-Roussillon, France, ²CH LE MANS, LE MANS, Pays de la Loire, France, ³Cabinet de Rhumatologie, Marseille, France, ⁴Nordic Pharma France, Paris, France, ⁵CHU Lille, Lille, Nord-Pas-de-Calais, France
Background/Purpose: Methotrexate (MTX) is the first line standard of care for the management of rheumatoid arthritis (RA). In the event of an inadequate response to…
Abstract Number: 1383 • ACR Convergence 2024
Proteomics and Machine Learning Accurately Predict Clinical Response to Etanercept Therapy in Patients with Rheumatoid Arthritis
Huaqun Zhu¹, Gong cheng¹, yingni Li¹, Yun Li¹, Feng Sun¹, Hongyan Wang¹, Qinqin li², Zhilun Li³, Ru Li⁴ and Zhanguo Li⁵, ¹Peking University People's Hospital, Beijing, China, ²Sansheng Guojian Pharmaceutical (Shanghai) Company, Shanghai, China (People's Republic), ³Sansheng Guojian Pharmaceutical (Shanghai) Company, Shanghai, ⁴Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China, ⁵People’s Hospital Peking University Health Sciences Centre, Beijing, China
Background/Purpose: Our study aimed to use machine-learning approaches to characterize the proteomics profiles of patients who were inadequate responders to Etanercept (ETN-IRs) and develop an…
Abstract Number: 1399 • ACR Convergence 2024
A First-in-Human Clinical Trial Evaluating the Safety and Pharmacokinetics of SOL-116, a Novel Humanized Monoclonal Antibody Targeting Bile Salt-Stimulated Lipase for the Treatment of RA
Karin Franck-Larsson¹, Susanne Lindquist², Agneta Wennerholm³, Johan Kolmert⁴, Maria Wanderoy³ and Olle Hernell², ¹Lipum AB, Uppsala, Sweden, ²Lipum AB; Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden, ³Lipum AB, Stockholm, Sweden, ⁴Lipum AB; Unit of Integrative Metabolomics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Bile Salt-Stimulated Lipase (BSSL) is a lipolytic enzyme secreted by the lactating mammary gland and exocrine pancreas. Elevated plasma levels of BSSL have been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].